Carolyn Buser‐Doepner
GlaxoSmithKline (United States)(US)Institut thématique Génétique, génomique et bioinformatique(FR)ID Genomics (United States)(US)
Publications by Year
Research Areas
DNA Repair Mechanisms, Genetic Associations and Epidemiology, Cancer-related Molecular Pathways, Genomics and Rare Diseases, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens(2019)1,391 cited
- → The promise and peril of chemical probes(2015)841 cited
- → Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting(2011)83 cited
- → MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation(2011)83 cited
- → Potent N-(1,3-Thiazol-2-yl)pyridin-2-amine Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors with Excellent Pharmacokinetics and Low Affinity for the hERG Ion Channel(2004)60 cited
- → Preclinical target validation using patient-derived cells(2015)53 cited